首页> 外国专利> CXCL12 (CHEMOKINE (C-X-C MOTIF) LIGAND 12) AND IGFBP2 INHIBITORS FOR THE APPLICATION IN THE TREATMENT OF DIABETES MELLITUS ASSOCIATED PANCREATIC CANCER

CXCL12 (CHEMOKINE (C-X-C MOTIF) LIGAND 12) AND IGFBP2 INHIBITORS FOR THE APPLICATION IN THE TREATMENT OF DIABETES MELLITUS ASSOCIATED PANCREATIC CANCER

机译:CXCL12(趋化因子(C-X-C MOTIF)配体12)和IGFBP2抑制剂在治疗糖尿病相关性胰腺癌中的应用

摘要

The subject of the invention is the application of CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the treatment of diabetes mellitus associated pancreatic cancer. The core of this invention is the discovery that the chronically increased glucose levels (chronic hyperglycemia) could may an important role in the development of the pancreatic cancer and that the development of the pancreatic cancer due to chronic hyperglycemia or an already developed pancreatic cancer may be prevented/inhibited/delayed by the inhibition of CXCL12 and IGFBP2. In addition the subject of the invention is the production of inhibitors for the application as a treatment of diabetes mellitus associated pancreatic cancer and pharmaceutical drugs containing the inhibitors.
机译:本发明的主题是CXCL12(趋化因子(C-X-C基序)配体12)和IGFBP2抑制剂在治疗糖尿病相关的胰腺癌中的应用。本发明的核心是发现长期升高的葡萄糖水平(慢性高血糖症)可能在胰腺癌的发展中起重要作用,并且由于慢性高血糖症或已经发展的胰腺癌的胰腺癌的发展可能是可能的。通过抑制CXCL12和IGFBP2来预防/抑制/延迟。另外,本发明的主题是抑制剂的制备,其用于治疗与糖尿病有关的胰腺癌和包含该抑制剂的药物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号